Nervgen Pharma (NGEN) Net Cash Flow (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Net Cash Flow came in at $56.5 million in Q2 2026, up 1547.09% year-over-year from $3.4 million in Q2 2025, and up 2687.16% quarter-over-quarter from $2.0 million in Q1 2026.
Powered by 
Analysis
Nervgen Pharma (NGEN) Net Cash Flow (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Net Cash Flow for 2 consecutive years, with $56.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Cash Flow rose 1547.09% year-over-year to $56.5 million in Q2 2026; TTM through Jun 2026 was $62.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.1 million, down 27.51% from the prior year.
- Net Cash Flow was $56.5 million for Q2 2026 at Nervgen Pharma, up from $2.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $56.5 million in Q2 2026 and troughed at $888133.6 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Nervgen Pharma | 152.26 Mn | 152.26 Mn | - | 56.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.49 Mn |
| Mar 31, 2026 | 2.03 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 888,133.63 |